The TCV Vaccine  Market represents a critical segment of the global immunization landscape, focusing on the prevention of typhoid fever caused by the bacterium Salmonella Typhi. Unlike traditional Vi polysaccharide vaccines, TCVs are conjugated to a protein carrier, which triggers a more robust and long-lasting immune response, even in infants as young as six months. This technological advantage makes TCVs the preferred choice for national immunization programs in endemic regions, offering a significantly higher degree of protection compared to older alternatives.

The market's primary application is within public health frameworks across Asia and Sub-Saharan Africa, where the burden of typhoid is most severe. As antibiotic resistance—specifically extensively drug-resistant (XDR) typhoid—becomes a global threat, the role of TCVs has shifted from a supplemental traveler's vaccine to a foundational public health tool. Major international health bodies like the WHO and Gavi are actively prioritizing the rollout of these vaccines to curb mortality rates and reduce the economic strain of enteric diseases on developing healthcare systems.

Market Segmentation:

The TCV Vaccines Market is segmented into Product Type, Age Group, and Distribution Channel. By Product Type, the market is categorized into Monovalent TCVs and Combination TCVs. By Age Group, the market is categorized into Infants (6 months to 2 years), Children (2 to 15 years), and Adults. By Distribution Channel, the market is categorized into Public (UNICEF/Gavi/Government Tenders) and Private (Hospitals/Specialty Clinics).

Growth Driver:

Rising Global Burden of Antimicrobial Resistance (AMR) in Typhoid Strains: The primary growth driver for the TCV market is the alarming rise of antibiotic-resistant Salmonella Typhi strains. Traditional treatments are becoming increasingly ineffective, leading to higher hospitalization costs and mortality rates. This crisis has prompted the World Health Organization (WHO) and Gavi, the Vaccine Alliance, to accelerate the integration of TCVs into routine childhood immunization schedules. By preventing the disease at the source, governments can mitigate the spread of drug-resistant pathogens, making TCV adoption a strategic necessity for global health security and biodefense.

Market Opportunity:

Expansion of Combination Vaccines and Pediatric Programs in Emerging Economies: A significant market opportunity lies in the development of Combination TCVs that protect against typhoid alongside other prevalent diseases like Paratyphoid or Rotavirus. Currently, the market is dominated by monovalent options, but the next wave of innovation is expected to focus on reducing the number of injections in pediatric schedules. Furthermore, as countries like Bangladesh, Malawi, and Zimbabwe successfully implement nationwide "catch-up" campaigns, there is a massive opening for manufacturers to secure long-term supply contracts through public tenders, specifically targeting the high-volume pediatric demographic in low-and-middle-income countries (LMICs).

Detailed Segmentation:

TCV Vaccines Market, Segmentation The TCV Vaccines Market is segmented on the basis of Product Type, Age Group, and Distribution Channel.

Product Type The Product Type segment is further classified into Monovalent TCVs and Combination TCVs. Among these, the Monovalent TCVs sub-segment accounted for the highest market share in 2024. This dominance is due to the early WHO prequalification of products like Typbar TCV, which has allowed them to be the primary tool for large-scale Gavi-supported rollout programs. Monovalent TCVs provide targeted, high-efficacy protection and are currently the only widely available conjugate option for children under two years of age in endemic regions.

Distribution Channel The Distribution Channel segment is further classified into Public and Private. Among these, the Public sub-segment accounted for the highest market share in 2024. The public sector, driven by UNICEF and national governments, controls the majority of the market volume because typhoid is primarily a disease of poverty and poor sanitation. Government-led immunization drives and large-scale procurement through international agencies ensure that the vaccine reaches the most vulnerable populations, making public tenders the largest revenue and volume generator for manufacturers.

Some of The Leading/Active Market Players Are-

• Bharat Biotech International Ltd. (India)
• GSK plc (UK)
• Sanofi S.A. (France)
• Serum Institute of India Pvt. Ltd. (India)
• Biological E. Limited (India)
• PT Bio Farma (Indonesia)
• Zydus Lifesciences Ltd. (India)
• Emergent BioSolutions Inc. (USA)
• Bavarian Nordic (Denmark)
• EuBiologics Co., Ltd. (South Korea)
• SK bioscience Co., Ltd. (South Korea)
• and other active players.

Key Industry Developments

News 1: In October 2025, the Government of Bangladesh, supported by UNICEF and Gavi, launched the world’s largest TCV campaign, aiming to vaccinate 50 million children aged 9 months to 15 years. This monumental rollout highlights the critical role of international collaborations in the TCV market. By targeting a significant portion of the youth population in a highly endemic country, this initiative not only prevents thousands of deaths but also sets a benchmark for other nations to transition TCVs into routine immunization schedules.

News 2: In November 2025, PATH and EuBiologics announced positive Phase III clinical trial results for EuTYPH-C, a new multi-dose TCV candidate, showing it to be non-inferior to current WHO-prequalified products. This development is vital for market stability, as the entry of new WHO-prequalified manufacturers diversifies the supply chain. The multi-dose presentation is specifically designed to improve logistics and lower cold-chain costs in resource-limited settings, presenting a lucrative opportunity for expansion in the African and Southeast Asian markets.

Key Findings of the Study

• Asia Pacific remains the dominant region due to high disease prevalence and leading vaccine producers in India.
• The Public Distribution Channel accounts for over 65% of the market share, fueled by Gavi and UNICEF initiatives.
• The Infants and Children segments are the primary end-users, with vaccines now approved for those as young as 9 months.
• A major trend is the development of multi-dose and combination vaccines to streamline global supply chains.

[CTA: Download the full report to access detailed analysis of the TCV pipeline and national immunization forecasts.]

About Us

At Introspective Market Research Private Limited, we are a forward-thinking research consulting firm committed to driving growth in the TCV Vaccines Market. With deep insights, strategic solutions, and holistic research, we empower businesses to achieve success and dominance in the global Hormone Replacement Therapy Market and Infectious Disease industry.

📞 Contact Us

Introspective Market Research Pvt. Ltd.

 Phone: +91-91753-37569

Email: sales@introspectivemarketresearch.com

Web: www.introspectivemarketresearch.com